AZATHIOPRINE TABLET

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

AZATHIOPRINE

Dostępny od:

SANIS HEALTH INC

Kod ATC:

L04AX01

INN (International Nazwa):

AZATHIOPRINE

Dawkowanie:

50MG

Forma farmaceutyczna:

TABLET

Skład:

AZATHIOPRINE 50MG

Droga podania:

ORAL

Sztuk w opakowaniu:

100

Typ recepty:

Prescription

Dziedzina terapeutyczna:

IMMUNOSUPPRESSIVE AGENTS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0101830001; AHFS:

Status autoryzacji:

CANCELLED POST MARKET

Data autoryzacji:

2017-07-31

Charakterystyka produktu

_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
AZATHIOPRINE
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
SANIS HEALTH INC.
333 CHAMPLAIN ST.
DIEPPE, NEW BRUNSWICK
DATE OF PREPARATION:
E1A 1P2
July 7, 2015
CONTROL #: 184965
_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_Page 2 of 25_
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL INFORMATION
..............................................
3
SUMMARY PRODUCT INFORMATION
......................................................
3
INDICATIONS AND CLINICAL USE
............................................................
3
CONTRAINDICATIONS
.................................................................................
3
WARNINGS AND PRECAUTIONS
................................................................
4
ADVERSE REACTIONS
..................................................................................
8
DRUG INTERACTIONS
..................................................................................
10
DOSAGE AND ADMINISTRATION
..............................................................
12
OVERDOSAGE
................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................
13
STORAGE AND STABILITY
..........................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.......................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING .............................
15
PART II: SCIENTIFIC INFORMATION
........................................................................
16
PHARMACEUTICAL INFORMATION
..........................................................
16
CLINICAL TRIALS
..........................................................................................
16
TOXICOLOGY
.....................